Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 441

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantation

Open access
Todo, Satoru, Yamashita, Kenichiro, Goto, Ryoichi, Zaitsu, Masaaki, Nagatsu, Akihisa, Oura, Tetsu, Watanabe, Masaaki, Aoyagi, Takeshi, Suzuki, Tomomi, Shimamura, Tsuyoshi, Kamiyama, Toshiya, Sato, Norihiro, Sugita, Junichi, Hatanaka, Kanako, Bashuda, Hisashi, Habu, Sonoko, Demetris, Anthony J., Okumura, Ko·2016·Hepatology
DOI 10.1002/hep.28459
Open this paper in CoChat — free account

Abstract

Potent immunosuppressive drugs have significantly improved early patient survival after liver transplantation (LT). However, long‐term results remain unsatisfactory because of adverse events that are largely associated with lifelong immunosuppression. To solve this problem, different strategies have been undertaken to induce operational tolerance, for example, maintenance of normal graft function and histology without immunosuppressive therapy, but have achieved limited success. In this pilot study, we aimed to induce tolerance using a novel regulatory T‐cell‐based cell therapy in living donor LT. Adoptive transfer of an ex vivo ‐generated regulatory T‐cell‐enriched cell product was conducted in 10 consecutive adult patients early post‐LT. Cells were generated using a 2‐week coculture of recipient lymphocytes with irradiated donor cells in the presence of anti‐CD80/86 monoclonal antibodies. Immunosuppressive agents were tapered from 6 months, reduced every 3 months, and completely discontinued by 18 months. After the culture, the generated cells displayed cell‐number‐dependent donor‐specific inhibition in the mixed lymphocyte reaction. Infusion of these cells caused no significant adverse events. Currently, all patients are well with normal graft function and histology. Seven patients have completed successful weaning and cessation of immunosuppressive agents. At present, they have been drug free for 16‐33 months; 4 patients have been drug free for more than 24 months. The other 3 recipients with autoimmune liver diseases developed mild rejection during weaning and then resumed conventional low‐dose immunotherapy. Conclusions: A cell therapy using an ex vivo ‐generated regulatory T‐cell‐enriched cell product is safe and effective for drug minimization and operational tolerance induction in living donor liver recipients with nonimmunological liver diseases. (H epatology 2016;64:632‐643)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28459

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 441

Metadata

Authors
Todo, S., Yamashita, K., Goto, R., Zaitsu, M., Nagatsu, A., Oura, T., Watanabe, M., Aoyagi, T., Suzuki, T., Shimamura, T., Kamiyama, T., Sato, N., Sugita, J., Hatanaka, K., Bashuda, H., Habu, S., Demetris, A. J., & Okumura, K.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-03-10
Volume
64
Issue
2
Pages
632-643
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
DOI
10.1002/hep.28459
OpenAlex
W2284630235
Cited by
441
References
40
FWCI
41.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantation. https://app.cochat.ai/papers/10.1002/hep.28459
The paper
Todo, S., Yamashita, K., Goto, R., Zaitsu, M., Nagatsu, A., Oura, T., Watanabe, M., Aoyagi, T., Suzuki, T., Shimamura, T., Kamiyama, T., Sato, N., Sugita, J., Hatanaka, K., Bashuda, H., Habu, S., Demetris, A. J., & Okumura, K. (2016). A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantation. Hepatology. https://doi.org/10.1002/hep.28459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.